| | | | Declaration of Interests Register | | | | | | |
|---|---|--|--|--|---|--|--|--|--|
| Technology Appraisal Committee A P | | | | | Publi | Publication Date: 07/08/2019 | | | |
| Topic: Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367] | | | | | | | | | |
| Role with NICE | Type of interest | Description of interest | Relevant dates | | | Comments | | | |
| | | | Interest arose | Interest declared | Interest ceased | | | | |
| TAC (A) Committee Member | Indirect | Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication | 2017 | 09/04/2019 | Ongoing | Declare and participate Chair: Jane Adam Associate Director: Janet Robertson | | | |
| TAC (A) Committee Member | Indirect | Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a lay panellist for Cemiplimab | August 2018 | 09/04/2019 | March 2019 | Declare and Participate Chair: Jane Adam Associate Director: Janet Robertson Programme Director: Helen Knight | | | |
| | Ab for treating cut Role with NICE TAC (A) Committee Member TAC (A) Committee | Tab for treating cutaneous squamou Role with NICE Type of interest TAC (A) Indirect Committee Member TAC (A) Indirect TAC (A) Indirect TAC (A) Indirect TAC (A) Indirect | Tab for treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a | Ab for treating cutaneous squamous cell carcinoma [ID1367]Role with NICEType of interestDescription of interestRInterest aroseInterest aroseInterest aroseTAC (A) Committee MemberIndirectEmployer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication2017TAC (A) Committee MemberIndirectAttended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as aAugust 2018 | Treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest Relevant dates Interest Interest Interest Interest TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication 2017 09/04/2019 TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a August 2018 09/04/2019 | Ab for treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest Relevant dates Interest arose Interest declared Interest ceased TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication 2017 09/04/2019 Ongoing TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a August 2018 09/04/2019 March 2019 | | | |

